Vivodyne Announces $38 Million Seed Financing Led By Khosla Ventures To Develop Lab-Grown Human Organs
Vivodyne Announces $38 Million Seed Financing Led By Khosla Ventures To Develop Lab-Grown Human Organs
11/22/23, 1:05 PM
Location
brisbaneMoney raised
$38 million
Industry
biotechnology
Round Type
seed
Investors
Bison Ventures, Mbx Capital, Cs Ventures, Kairos Ventures, Khosla Ventures
Vivodyne, a biotech that discovers and develops more effective drugs by testing them on lab-grown human organs, today announced the close of $38 million in total seed financing, led by Khosla Ventures, with participation from Kairos Ventures, CS Ventures, MBX Capital, and Bison Ventures.
Company Info
Location
brisbane, california, united states
Additional Info
Vivodyne is a biotechnology company that accelerates the development of more effective medicines by testing on thousands of lifelike, lab-grown human organ tissues at a time. Robots are used to grow and experiment on lab-grown human organs at massive scale, creating datasets of unparalleled realism and breadth to power a predictive AI platform technology. Vivodyne was founded by University of Pennsylvania bioengineers Andrei Georgescu and Dan Huh.